231 related articles for article (PubMed ID: 21757247)
1. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).
Baumann M; Herrmann T; Koch R; Matthiessen W; Appold S; Wahlers B; Kepka L; Marschke G; Feltl D; Fietkau R; Budach V; Dunst J; Dziadziuszko R; Krause M; Zips D;
Radiother Oncol; 2011 Jul; 100(1):76-85. PubMed ID: 21757247
[TBL] [Abstract][Full Text] [Related]
2. GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial.
Soliman M; Yaromina A; Appold S; Zips D; Reiffenstuhl C; Schreiber A; Thames HD; Krause M; Baumann M
Radiother Oncol; 2013 Mar; 106(3):299-304. PubMed ID: 23333018
[TBL] [Abstract][Full Text] [Related]
3. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
[TBL] [Abstract][Full Text] [Related]
4. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study.
Bonner JA; McGinnis WL; Stella PJ; Marschke RF; Sloan JA; Shaw EG; Mailliard JA; Creagan ET; Ahuja RK; Johnson PA
Cancer; 1998 Mar; 82(6):1037-48. PubMed ID: 9506347
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer.
Rojas AM; Lyn BE; Wilson EM; Williams FJ; Shah N; Dickson J; Saunders MI
Cancer; 2006 Sep; 107(6):1321-30. PubMed ID: 16902985
[TBL] [Abstract][Full Text] [Related]
6. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.
Saunders MI; Rojas A; Lyn BE; Pigott K; Powell M; Goodchild K; Hoskin PJ; Phillips H; Verma N
Br J Cancer; 1998 Nov; 78(10):1323-8. PubMed ID: 9823973
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial.
Ricardi U; Filippi AR; Guarneri A; Giglioli FR; Ciammella P; Franco P; Mantovani C; Borasio P; Scagliotti GV; Ragona R
Lung Cancer; 2010 Apr; 68(1):72-7. PubMed ID: 19556022
[TBL] [Abstract][Full Text] [Related]
9. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer.
Saunders MI; Rojas A; Lyn BE; Wilson E; Phillips H
Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):352-60. PubMed ID: 12555873
[TBL] [Abstract][Full Text] [Related]
10. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
[TBL] [Abstract][Full Text] [Related]
11. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
Jeremić B; Milicić B
Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
[TBL] [Abstract][Full Text] [Related]
12. Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome.
Pemberton LS; Din OS; Fisher PM; Hatton MQ
Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):161-7. PubMed ID: 19111452
[TBL] [Abstract][Full Text] [Related]
13. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
[TBL] [Abstract][Full Text] [Related]
14. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study.
Kong FM; Ten Haken RK; Schipper MJ; Sullivan MA; Chen M; Lopez C; Kalemkerian GP; Hayman JA
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):324-33. PubMed ID: 16168827
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two dimensional and three dimensional radiotherapy treatment planning in locally advanced non-small cell lung cancer treated with continuous hyperfractionated accelerated radiotherapy weekend less.
Wilson EM; Joy Williams F; Lyn BE; Aird EG
Radiother Oncol; 2005 Mar; 74(3):307-14. PubMed ID: 15763312
[TBL] [Abstract][Full Text] [Related]
16. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
[TBL] [Abstract][Full Text] [Related]
17. Routine use of continuous, hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer: a five-center experience.
Din OS; Lester J; Cameron A; Ironside J; Gee A; Falk S; Morgan SA; Worvill J; Hatton MQ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):716-22. PubMed ID: 18355975
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation.
Moreno-Jiménez M; Aristu J; López-Picazo JM; Ramos LI; Gúrpide A; Gómez-Iturriaga A; Valero J; Martínez-Monge R
Radiother Oncol; 2008 Sep; 88(3):342-50. PubMed ID: 18558448
[TBL] [Abstract][Full Text] [Related]
19. Neo-adjuvant chemotherapy followed by either continuous hyper-fractionated accelerated radiation therapy week-end less or conventional chemo-radiotherapy in locally advanced NSCLC-A randomised prospective single institute study.
Kumar R; Kumar HS; Paramanandhan M; Purohit R; Sharma N; Jakhar SL; Sharma S; Maharia S; Rai RK
J Cancer Res Ther; 2020; 16(4):860-866. PubMed ID: 32930131
[TBL] [Abstract][Full Text] [Related]
20. Different fraction schedules and combinations with chemotherapy in radiation treatment of non-small cell lung cancer.
Brattström D; Bergqvist M; Hesselius P; Wagenius G; Brodin O
Anticancer Res; 2000; 20(3B):2087-90. PubMed ID: 10928157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
